Rectal tumours disappear in experimental cancer drug trial, but too ...

Rectal tumours disappear in experimental cancer drug trial, but too ...

ABC News - 10 Jun 2022
An experimental drug cleared tumours from a dozen people with a specific type of rectal cancer, but experts say there's loads more work to be done.

Dr Powell on the Implications of the FDA Approval of Dostarlimab for Endometrial Cancer

OncLive - 07 Nov 2024
Dr Powell on the Implications of the FDA Approval of Dostarlimab for Endometrial Cancer ...

Dostarlimab's Promise in dMMR Locally Advanced Rectal Cancer

Targeted Oncology - 31 Oct 2024
Dostarlimab's Promise in dMMR Locally Advanced Rectal Cancer ...

Imfinzi, Keytruda Approved for Some Endometrial Cancers

National Cancer Institute (.gov) - 06 Aug 2024
Imfinzi, Keytruda Approved for Some Endometrial Cancers ...

Case Report: Dostarlimab for treatment of aggressive cutaneous squamous cell carcinoma

Frontiers - 24 Jun 2024
Case Report: Dostarlimab for treatment of aggressive cutaneous squamous cell carcinoma ...

FDA Expands Dostarlimab (Jemperli) Approval in Endometrial Cancer

Oncology News Central - 02 Aug 2024
FDA Expands Dostarlimab (Jemperli) Approval in Endometrial Cancer ...

A 100% response rate suggests dostarlimab is ‘definitive’ therapy for rectal cancer

Healio - 05 Jun 2024
A 100% response rate suggests dostarlimab is ‘definitive’ therapy for rectal cancer ...

GSK's Jemperli (dostarlimab) plus chemotherapy approved in Singapore as the first frontline immuno-oncology treatment for dMMR/MSI-H primary advanced or recurrent endometrial cancer

PR Newswire - 07 Aug 2024
GSK's Jemperli (dostarlimab) plus chemotherapy approved in Singapore as the first frontline immuno-oncology treatment for dMMR/MSI-H primary advanced or recurrent endometrial cancer ...

Belrestotug/Dostarlimab Improves Responses in PD-L1–High Lung Cancer

www.oncnursingnews.com/ - 24 Sep 2024
Belrestotug/Dostarlimab Improves Responses in PD-L1–High Lung Cancer ...

Dostarlimab/Chemo Yields “Unprecedented” OS in dMMR Endometrial Cancer

Cancer Network - 20 Mar 2024
Dostarlimab/Chemo Yields “Unprecedented” OS in dMMR Endometrial Cancer ...

US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit

Business Wire - 01 Aug 2024
US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit ...

Dostarlimab Plus Chemotherapy Opens Doors Across Endometrial Cancer Subtypes

OncLive - 23 Aug 2024
Dostarlimab Plus Chemotherapy Opens Doors Across Endometrial Cancer Subtypes ...

Dostarlimab: Game Changer in Rectal Cancer Treatment?

Targeted Oncology - 17 Jun 2024
Dostarlimab: Game Changer in Rectal Cancer Treatment? ...

Dostarlimab Aces Phase 2 Rectal Cancer Study, Posting 100% Complete Response Rate

Oncology News Central - 14 Jun 2024
Dostarlimab Aces Phase 2 Rectal Cancer Study, Posting 100% Complete Response Rate ...

Frontline Belrestotug/Dostarlimab Boosts Responses Vs Dostarlimab Alone in PD-L1–High NSCLC

OncLive - 14 Sep 2024
Frontline Belrestotug/Dostarlimab Boosts Responses Vs Dostarlimab Alone in PD-L1–High NSCLC ...

The Targeted Pulse: Dostarlimab Achieves 100% Clinical Complete Response, FDA Acknowledges BLA for Zolbetuximab, and More

Targeted Oncology - 09 Jun 2024
The Targeted Pulse: Dostarlimab Achieves 100% Clinical Complete Response, FDA Acknowledges BLA for Zolbetuximab, and More ...

Dostarlimab